Answers are grounded in this paper and cite their sources.
Early detection of iron deficiency during pregnancy and the postpartum period, a common condition associated with adverse maternal and neonatal outcomes, remains challenging with conventional iron markers. Reticulocyte hemoglobin indices, including reticulocyte hemoglobin equivalent and reticulocyte hemoglobin content, may enable earlier detection of iron-restricted erythropoiesis. We conducted a scoping review to map the clinical and research applications of these indices in pregnant and postpartum women. Following Joanna Briggs Institute methodology and PRISMA-ScR guidance, we searched PubMed, CENTRAL, Web of Science, and Ichushi Web for studies published from January 1, 1990, to May 31, 2025, and performed an updated search on April 21, 2026, for newly added or indexed records. Eligible studies involved pregnant women or women within 3 months postpartum in whom reticulocyte hemoglobin indices were evaluated for clinical or research purposes. We also constructed an evidence map to visualize the distribution of evidence and research gaps. Thirty-five studies were included. Evidence was most developed for diagnostic accuracy for iron deficiency and associations with iron-related biomarkers. Reticulocyte hemoglobin indices generally showed good diagnostic performance, although reported cut-off values varied widely across studies. Data from mid-to-late pregnancy remained limited. Studies using reticulocyte hemoglobin indices as indicators of response to iron therapy are increasing. Some studies examined longitudinal changes and reference values across pregnancy and the postpartum period; however, these studies were methodologically limited. Three studies examined associations between maternal reticulocyte hemoglobin indices and neonatal parameters, whereas no study evaluated maternal clinical outcomes. Overall, reticulocyte hemoglobin indices appear promising for assessing iron status and monitoring response to iron therapy in perinatal populations. However, substantial heterogeneity in study design, reference standards, and analytical platforms, together with limited longitudinal and outcome-oriented evidence, currently constrains broader clinical implementation.
No takes yet. Share an insight, caveat, or question.
Ohtsuki et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: